Optimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus.

2.50
Hdl Handle:
http://hdl.handle.net/11287/618122
Title:
Optimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus.
Authors:
Taylor, E. L.; Armstrong, K. R.; Perrett, D.; Hattersley, Andrew T.; Winyard, Paul G.
Abstract:
Advanced oxidation protein products (AOPP) are reportedly elevated in the plasma of patients with a number of diseases, including diabetes mellitus, that involve oxidative stress. However, the accurate measurement of AOPP in human plasma is hampered by the formation of a precipitate following the addition of potassium iodide and glacial acetic acid according to the published assay procedure. Here we describe a modification of the AOPP assay which eliminates interference by precipitation and provides a robust, reliable, and reproducible protocol for the measurement of iodide oxidising capacity in plasma samples (intra-assay CV 1.7-5.3%, interassay CV 5.3-10.5%). The improved method revealed a significant association of AOPP levels with age (p < 0.05) and hypertension (p = 0.01) in EDTA-anticoagulated plasma samples from 52 patients with diabetes and 38 nondiabetic control subjects, suggesting a possible link between plasma oxidising capacity and endothelial and/or vascular dysfunction. There was no significant difference between AOPP concentrations in diabetic (74.8 ± 7.2 μM chloramine T equivalents) and nondiabetic (75.5 ± 7.0 μM chloramine T equivalents) individuals.
Citation:
Optimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus. 2015, 2015:496271 Oxid Med Cell Longev
Publisher:
Hindawi
Journal:
Oxidative medicine and cellular longevity
Issue Date:
2015
URI:
http://hdl.handle.net/11287/618122
DOI:
10.1155/2015/496271
PubMed ID:
26113954
Additional Links:
http://dx.doi.org/10.1155/2015/496271
Note:
This article is freely available from the publisher's site - click on the 'Additional Link' above to access the full text.
Type:
Journal Article; Research Support, Non-U.S. Gov't
Language:
en
ISSN:
1942-0994
Appears in Collections:
2015 RD&E publications; Diabetes/Endocrine Services; Honorary contracts publications

Full metadata record

DC FieldValue Language
dc.contributor.authorTaylor, E. L.en
dc.contributor.authorArmstrong, K. R.en
dc.contributor.authorPerrett, D.en
dc.contributor.authorHattersley, Andrew T.en
dc.contributor.authorWinyard, Paul G.en
dc.date.accessioned2016-08-09T13:42:21Z-
dc.date.available2016-08-09T13:42:21Z-
dc.date.issued2015-
dc.identifier.citationOptimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus. 2015, 2015:496271 Oxid Med Cell Longeven
dc.identifier.issn1942-0994-
dc.identifier.pmid26113954-
dc.identifier.doi10.1155/2015/496271-
dc.identifier.urihttp://hdl.handle.net/11287/618122-
dc.description.abstractAdvanced oxidation protein products (AOPP) are reportedly elevated in the plasma of patients with a number of diseases, including diabetes mellitus, that involve oxidative stress. However, the accurate measurement of AOPP in human plasma is hampered by the formation of a precipitate following the addition of potassium iodide and glacial acetic acid according to the published assay procedure. Here we describe a modification of the AOPP assay which eliminates interference by precipitation and provides a robust, reliable, and reproducible protocol for the measurement of iodide oxidising capacity in plasma samples (intra-assay CV 1.7-5.3%, interassay CV 5.3-10.5%). The improved method revealed a significant association of AOPP levels with age (p < 0.05) and hypertension (p = 0.01) in EDTA-anticoagulated plasma samples from 52 patients with diabetes and 38 nondiabetic control subjects, suggesting a possible link between plasma oxidising capacity and endothelial and/or vascular dysfunction. There was no significant difference between AOPP concentrations in diabetic (74.8 ± 7.2 μM chloramine T equivalents) and nondiabetic (75.5 ± 7.0 μM chloramine T equivalents) individuals.en
dc.language.isoenen
dc.publisherHindawien
dc.relation.urlhttp://dx.doi.org/10.1155/2015/496271en
dc.rightsArchived with thanks to Oxidative medicine and cellular longevityen
dc.subjectWessex Classification Subject Headings::Endocrinology::Diabetesen
dc.titleOptimisation of an Advanced Oxidation Protein Products Assay: Its Application to Studies of Oxidative Stress in Diabetes Mellitus.en
dc.typeJournal Articleen
dc.typeResearch Support, Non-U.S. Gov'ten
dc.identifier.journalOxidative medicine and cellular longevityen
dc.description.noteThis article is freely available from the publisher's site - click on the 'Additional Link' above to access the full text.en
dc.type.versionPublisheden
All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.